Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery

Joseph DeRose, Juan P. Umana, Michael Argenziano, Katharine A. Catanese, Michael T. Gardocki, Margaret Flannery, Howard R. Levin, Benjamin C. Sun, Eric A. Rose, Mehmet C. Oz

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Objectives. Our recent experience with outpatient left ventricular assist device (LVAD) support is presented to demonstrate the possibilities and limitations of long-term outpatient mechanical circulatory assistance. Background. The experience with inpatient LVAD support as a bridge to transplantation has proved the efficacy of such therapy in improving circulatory hemodynamic status, restoring normal end-organ function and facilitating patient rehabilitation. With miniaturization of the power supplies and controllers, such mechanical circulatory support can now be accomplished in an outpatient setting. Methods. Between March 1993 and February 1997, 32 patients (26 male, 6 female, mean [ ± SEM] age 49 ± 15 years) underwent implantation of the ThermoCardiosystems (TCI) Heartmate vented electric (VE) LVAD. The VE LVAD is powered by batteries worn on shoulder holsters and is operated by a belt-mounted system controller, allowing unrestricted patient ambulation and hospital discharge. Results. Mean duration of support was 122 ± 26 days (range 3 to 605), with a survival rate to transplantation or explantation of 78%. Nineteen patients were discharged from the hospital on mean postoperative day 41 ± 4 (range 17 to 68), for an outpatient support time of 108 ± 30 days (range 2 to 466). Four patients underwent early transplantation and could not participate in the discharge program, and three patients currently await discharge. The complication rate was not statistically different from that encountered in our previous 52 patients with a pneumatic LVAD. Conclusions. Outpatient LVAD support is safe and provides improved quality of life for patients awaiting transplantation. Wearable and totally implantable LVADs should be studied as permanent treatment options for patients who are not candidates for heart transplantation.

Original languageEnglish (US)
Pages (from-to)1773-1777
Number of pages5
JournalJournal of the American College of Cardiology
Volume30
Issue number7
DOIs
StatePublished - Dec 1997
Externally publishedYes

Fingerprint

Heart-Assist Devices
Outpatients
Transplantation
Miniaturization
Electric Power Supplies
Heart Transplantation
Walking
Inpatients
Rehabilitation
Survival Rate
Hemodynamics
Quality of Life

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery. / DeRose, Joseph; Umana, Juan P.; Argenziano, Michael; Catanese, Katharine A.; Gardocki, Michael T.; Flannery, Margaret; Levin, Howard R.; Sun, Benjamin C.; Rose, Eric A.; Oz, Mehmet C.

In: Journal of the American College of Cardiology, Vol. 30, No. 7, 12.1997, p. 1773-1777.

Research output: Contribution to journalArticle

DeRose, J, Umana, JP, Argenziano, M, Catanese, KA, Gardocki, MT, Flannery, M, Levin, HR, Sun, BC, Rose, EA & Oz, MC 1997, 'Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery', Journal of the American College of Cardiology, vol. 30, no. 7, pp. 1773-1777. https://doi.org/10.1016/S0735-1097(97)00396-3
DeRose, Joseph ; Umana, Juan P. ; Argenziano, Michael ; Catanese, Katharine A. ; Gardocki, Michael T. ; Flannery, Margaret ; Levin, Howard R. ; Sun, Benjamin C. ; Rose, Eric A. ; Oz, Mehmet C. / Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery. In: Journal of the American College of Cardiology. 1997 ; Vol. 30, No. 7. pp. 1773-1777.
@article{527bff7040474b9d8a3f57603953b06a,
title = "Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery",
abstract = "Objectives. Our recent experience with outpatient left ventricular assist device (LVAD) support is presented to demonstrate the possibilities and limitations of long-term outpatient mechanical circulatory assistance. Background. The experience with inpatient LVAD support as a bridge to transplantation has proved the efficacy of such therapy in improving circulatory hemodynamic status, restoring normal end-organ function and facilitating patient rehabilitation. With miniaturization of the power supplies and controllers, such mechanical circulatory support can now be accomplished in an outpatient setting. Methods. Between March 1993 and February 1997, 32 patients (26 male, 6 female, mean [ ± SEM] age 49 ± 15 years) underwent implantation of the ThermoCardiosystems (TCI) Heartmate vented electric (VE) LVAD. The VE LVAD is powered by batteries worn on shoulder holsters and is operated by a belt-mounted system controller, allowing unrestricted patient ambulation and hospital discharge. Results. Mean duration of support was 122 ± 26 days (range 3 to 605), with a survival rate to transplantation or explantation of 78{\%}. Nineteen patients were discharged from the hospital on mean postoperative day 41 ± 4 (range 17 to 68), for an outpatient support time of 108 ± 30 days (range 2 to 466). Four patients underwent early transplantation and could not participate in the discharge program, and three patients currently await discharge. The complication rate was not statistically different from that encountered in our previous 52 patients with a pneumatic LVAD. Conclusions. Outpatient LVAD support is safe and provides improved quality of life for patients awaiting transplantation. Wearable and totally implantable LVADs should be studied as permanent treatment options for patients who are not candidates for heart transplantation.",
author = "Joseph DeRose and Umana, {Juan P.} and Michael Argenziano and Catanese, {Katharine A.} and Gardocki, {Michael T.} and Margaret Flannery and Levin, {Howard R.} and Sun, {Benjamin C.} and Rose, {Eric A.} and Oz, {Mehmet C.}",
year = "1997",
month = "12",
doi = "10.1016/S0735-1097(97)00396-3",
language = "English (US)",
volume = "30",
pages = "1773--1777",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery

AU - DeRose, Joseph

AU - Umana, Juan P.

AU - Argenziano, Michael

AU - Catanese, Katharine A.

AU - Gardocki, Michael T.

AU - Flannery, Margaret

AU - Levin, Howard R.

AU - Sun, Benjamin C.

AU - Rose, Eric A.

AU - Oz, Mehmet C.

PY - 1997/12

Y1 - 1997/12

N2 - Objectives. Our recent experience with outpatient left ventricular assist device (LVAD) support is presented to demonstrate the possibilities and limitations of long-term outpatient mechanical circulatory assistance. Background. The experience with inpatient LVAD support as a bridge to transplantation has proved the efficacy of such therapy in improving circulatory hemodynamic status, restoring normal end-organ function and facilitating patient rehabilitation. With miniaturization of the power supplies and controllers, such mechanical circulatory support can now be accomplished in an outpatient setting. Methods. Between March 1993 and February 1997, 32 patients (26 male, 6 female, mean [ ± SEM] age 49 ± 15 years) underwent implantation of the ThermoCardiosystems (TCI) Heartmate vented electric (VE) LVAD. The VE LVAD is powered by batteries worn on shoulder holsters and is operated by a belt-mounted system controller, allowing unrestricted patient ambulation and hospital discharge. Results. Mean duration of support was 122 ± 26 days (range 3 to 605), with a survival rate to transplantation or explantation of 78%. Nineteen patients were discharged from the hospital on mean postoperative day 41 ± 4 (range 17 to 68), for an outpatient support time of 108 ± 30 days (range 2 to 466). Four patients underwent early transplantation and could not participate in the discharge program, and three patients currently await discharge. The complication rate was not statistically different from that encountered in our previous 52 patients with a pneumatic LVAD. Conclusions. Outpatient LVAD support is safe and provides improved quality of life for patients awaiting transplantation. Wearable and totally implantable LVADs should be studied as permanent treatment options for patients who are not candidates for heart transplantation.

AB - Objectives. Our recent experience with outpatient left ventricular assist device (LVAD) support is presented to demonstrate the possibilities and limitations of long-term outpatient mechanical circulatory assistance. Background. The experience with inpatient LVAD support as a bridge to transplantation has proved the efficacy of such therapy in improving circulatory hemodynamic status, restoring normal end-organ function and facilitating patient rehabilitation. With miniaturization of the power supplies and controllers, such mechanical circulatory support can now be accomplished in an outpatient setting. Methods. Between March 1993 and February 1997, 32 patients (26 male, 6 female, mean [ ± SEM] age 49 ± 15 years) underwent implantation of the ThermoCardiosystems (TCI) Heartmate vented electric (VE) LVAD. The VE LVAD is powered by batteries worn on shoulder holsters and is operated by a belt-mounted system controller, allowing unrestricted patient ambulation and hospital discharge. Results. Mean duration of support was 122 ± 26 days (range 3 to 605), with a survival rate to transplantation or explantation of 78%. Nineteen patients were discharged from the hospital on mean postoperative day 41 ± 4 (range 17 to 68), for an outpatient support time of 108 ± 30 days (range 2 to 466). Four patients underwent early transplantation and could not participate in the discharge program, and three patients currently await discharge. The complication rate was not statistically different from that encountered in our previous 52 patients with a pneumatic LVAD. Conclusions. Outpatient LVAD support is safe and provides improved quality of life for patients awaiting transplantation. Wearable and totally implantable LVADs should be studied as permanent treatment options for patients who are not candidates for heart transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0031542957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031542957&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(97)00396-3

DO - 10.1016/S0735-1097(97)00396-3

M3 - Article

C2 - 9385906

AN - SCOPUS:0031542957

VL - 30

SP - 1773

EP - 1777

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 7

ER -